SELLAS Life Sciences (SLS) Other Non Operating Income (2010 - 2019)
SELLAS Life Sciences (SLS) posted quarterly Other Non Operating Income of $668000.0 for Q4 2019, down 12.79% quarter-over-quarter from $766000.0 in Q3 2018.
Powered by 
Analysis
SELLAS Life Sciences (SLS) Other Non Operating Income (2010 - 2019) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Other Non Operating Income for 9 consecutive years, with $668000.0 the latest figure, recorded in Q4 2019.
- In Q4 2019, Other Non Operating Income changed N/A year-over-year to $668000.0; the TTM figure through Dec 2019 stood at $1.4 million (up 87.21% YoY), while the FY2020 annual figure was $208000.0, down 68.86% from the prior year.
- Other Non Operating Income retreated to $668000.0 in Q4 2019 per SLS's latest filing, from $766000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $766000.0 in Q3 2018 and bottomed at -$321000.0 in Q1 2015.
- Historically, Other Non Operating Income has averaged $253285.7 across 4 years, with a median of $307000.0 in 2015.
- On a YoY basis, Other Non Operating Income climbed as much as 116.9% in 2015 and fell as far as 94.55% in 2015.
- SELLAS Life Sciences' Other Non Operating Income stood at $440000.0 in 2015, then tumbled by 138.64% to -$170000.0 in 2016, then soared by 550.59% to $766000.0 in 2018, then fell by 12.79% to $668000.0 in 2019.
- Business Quant data shows SLS's Other Non Operating Income at $668000.0 in Q4 2019, $766000.0 in Q3 2018, and -$170000.0 in Q1 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 10 | SELLAS Life Sciences | 2.66 Bn | 2.66 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | 668,000.00 |
| Sep 30, 2018 | 766,000.00 |
| Mar 31, 2016 | -170,000.00 |
| Dec 31, 2015 | 440,000.00 |
| Sep 30, 2015 | 307,000.00 |
| Jun 30, 2015 | 83,000.00 |
| Mar 31, 2015 | -321,000.00 |
| Dec 31, 2014 | 229,000.00 |
| Sep 30, 2014 | 597,000.00 |
| Jun 30, 2014 | -491,000.00 |
| Mar 31, 2014 | -165,000.00 |
| Dec 31, 2013 | 2.14 Mn |
| Sep 30, 2013 | 693,000.00 |
| Jun 30, 2013 | -70,000.00 |
| Mar 31, 2013 | -5.44 Mn |
| Dec 31, 2012 | 11.55 Mn |
| Sep 30, 2012 | -733,000.00 |
| Jun 30, 2012 | 5.93 Mn |
| Mar 31, 2012 | -19.11 Mn |
| Dec 31, 2011 | 7.36 Mn |